newsfilter
← Earnings
Earnings Releases·

OnKure Therapeutics — Third Quarter 2026 Earnings Summary

OnKure Therapeutics reported a net loss of $17.8 million, or $0.36 per share, for the third quarter ended September 30, 2026, with total operating expenses reaching $19.4 million. The company holds $163.3 million in cash and marketable securities, providing a projected runway into 2029. OnKure is advancing its lead candidates OKI-355 for vascular anomalies and OKI-345 for breast cancer, with Investigational New Drug submissions planned for the first half of 2027. Additionally, the company launched the PANORAMA registry to characterize the natural disease course and treatment patterns of individuals living with vascular anomalies.

Company
ONKURE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology